*Purpose: To prevent transmission of SARS CoV 2 via solid organ donation from deceased donors.

*Methods: Comprehensive medical and psychosocial evaluation of potential deceased organ donors included a risk assessment for active infection w2ith SARS CoV 2 which was considered an absolute contraindication. Patients lacking active infection for whom authorization for donation was present, underwent testing for detectable SARS CoV 2 in specimens from the nasopharynx (PCR), bronchoalveolar lavage (PCR) and blood (antibody).

*Results: From 3/16/2020 – 12/2/2020 a total of 828 specimens were collected from 208 patients. Nearly all samples were negative for SARS CoV 2. 7 patients were confirmed to have antibody to SARS CoV 2; 6 became donors and 1 was ruled out. Nasopharyngeal specimens were PCR positive in 7 patients, 6 pf them were ruled out. The 7th patient was remotely infected and also was antibody positive; this patient did become a donor.No reports of donor transmission of SARS CoV 2 have been mreport3ed to us.

*Conclusions: Active evolution of the evaluation of SARS CoV 2 in deceased organ donor candidates has taken place during the initial phase of the pandemic. Systematic testing of nasopharyngeal, bronchoalveolar lavage and antibody status whenever feasible, facilitated donation by most authorized donors. This strategy has resulted in multiple organ transplants without evidence of SARS CoV -2 transmission.

« Back to 2021 American Transplant Congress